Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's disease

Not Applicable

• Conditions: Crohn' s disease

• Registration Number: JPRN-UMIN000022270
• Lead Sponsor: Saitama Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

Not provided

Exclusion Criteria

refractory patients for adalimumab

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
effective rates